Results 141 to 150 of about 106,790 (296)
This work investigates the selective inhibition of MAO enzymes by varying the substitution of electron‐withdrawing and donating groups on the phenyl rings of tetrahydropyridines (4 a–4 o). Compounds 4 l and 4 n exhibit promising IC50 values of 0.40±0.05 and 1.01±0.03 μM against MAO‐A and MAO‐B, respectively.
Obaid ur Rehman Khan+10 more
wiley +1 more source
Antipsychotic Polypharmacy, Part 1: Therapeutic Option or Dirty Little Secret?
Stephen M. Stahl
openalex +2 more sources
Discrepancies on prescribing antipsychotics [PDF]
Sonia Dollfus, Jim van Os, M. Petit
openalex +1 more source
Advances in Molecularly Imprinted Polymers for Bone Biomarker Detection and Therapeutic Applications
This review highlights the emerging applications of molecularly imprinted polymers (MIPs) in bone regeneration and diagnosis. MIPs facilitate osteogenic treatments by guiding stem cell differentiation and delivering bioactive molecules and enable precise detection of bone turnover biomarkers via MIP‐based sensors, offering promising strategies for next‐
Ren Yang+8 more
wiley +1 more source
The antipsychotics functional index (AFI) in schizophrenia. [PDF]
Marinescu GC+3 more
europepmc +1 more source
ABSTRACT Deficits in schizophrenia are linked to abnormalities in the glutamate (Glu) system, which are believed to result in neurological soft signs (NSS) and negative symptoms. This study investigated the relationship between Glu levels of the anterior cingulate cortex (ACC) and NSS, particularly sensory integration, in individuals with high and low ...
Yun‐Ru Wang+12 more
wiley +1 more source
Maintenance of antipsychotic efficacy with Amisulpride: Results of a long-term study versus haloperidol [PDF]
L Colonna, W. Rein, S. Turjanski
openalex +1 more source
ABSTRACT Despite predicting poor functional outcomes and being a significant patient burden, there are no approved pharmacotherapies to treat symptoms of cognitive impairment associated with schizophrenia (CIAS). Iclepertin (BI 425809) is a potent and selective inhibitor of glycine transporter‐1 (GlyT1) that was in Phase III development for the ...
Elin M. Matsson+3 more
wiley +1 more source
A cross-sectional survey of sexual dysfunction in patients taking antipsychotic medication [PDF]
Sue Smith+4 more
openalex +1 more source